ReviewJournal of cardiac failure2025
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.
Review in Journal of cardiac failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Temporal trends and post-transplant outcomes in anthracycline-induced cardiomyopathy: A contemporary United Network for Organ Sharing analysis.JHLT open · 2026Article
- Rheumatologists' expectations and perceptions of T-cell redirecting therapies: results from a cross-sectional survey.Rheumatology international · 2026Article
- Female Cardiovascular Health After Childhood Cancer.Current cardiology reports · 2026Review
- Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026Review
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- The growing need for heart failure specific risk prediction models and standardized care pathways in patients with cancer.Cardio-oncology (London, England) · 2026Article
- Balancing Oncological Care and Quality of Life: Diagnostic and Therapeutic Strategies for Chemotherapy-Induced Cardiotoxicity-A Narrative Review.Journal of clinical medicine · 2026Review
- Chemotherapy-Induced Right Ventricular Dysfunction.Medicina (Kaunas, Lithuania) · 2026Review
- The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.Journal of clinical medicine · 2026Review
- Endomyocardial Biopsies in the Diagnostic Workup of Immune Checkpoint Inhibitor Associated Myocarditis.Current heart failure reports · 2026Review
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.Biomedicines · 2026Review
- Heart Failure with Preserved Ejection Fraction in Women with Breast Cancer Prior to Cancer Treatment: Insights from a Cardio-Oncology Assessment.Journal of clinical medicine · 2026Article
- Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All.Current heart failure reports · 2026Review
- The Inflammation-Mediated Bidirectional Relationship Between Cardiovascular Disease and Cancer.Diseases (Basel, Switzerland) · 2026Review
- Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.Current oncology reports · 2026Review
- Cardio-Oncologic Considerations in Heart Failure With Mildly Reduced Ejection Fraction: Prevalence and Prognostic Impact of Malignancies.Journal of the American Heart Association · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Review
- Heart Substructure Radiation Dose and Cardiac Outcomes: Contemporary Evidence and Actionable Opportunities: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2026Review
- Clinical Characteristics and Outcomes of Heart Failure with Preserved Ejection Fraction Versus Reduced Ejection Fraction in Patients Receiving Anticancer Drugs.Cardiovascular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes. With the rapid growth of cancer therapies, many of which interfere with cardiovascular homeostasis, heart failure practitioners need to be familiar with prevention, risk stratification, diagnosis, and management strategies in cardio-oncology. This Heart Failure Society of America statement addresses the complexities of heart failure care among patients with active cancer diagnoses and cancer survivors. Risk stratification, monitoring and management of cardiotoxicity are presented across stages A through D heart failure, with focused discussion on heart failure with preserved ejection fraction and special populations, such as survivors of childhood and young-adulthood cancers. We provide an overview of the shared risk factors between cancer and heart failure, highlighting heart failure as a form of cardiotoxicity associated with many different cancer therapeutics. Finally, we discuss disparities in the care of patients with cancer and cardiac disease and present a framework for a multidisciplinary-team approach and critical collaboration among heart failure, oncology, palliative care, pharmacy, and nursing teams in the management of these complex patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.